FBLG
FibroBiologics, Inc.
$0.9310
-3.42%
$5.0M
No data for this timeframe.
Vol
Market Cap$5.0M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (75%)
Inst. Holders8 funds
Inst. Value$152.1K
Insider Activity6B / 0S
Insider Net $$73.0K
SEC Reports8
Press Releases5
Recent Activity
May 22, 2026
routine
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
In animal studies, human dermal fibroblast spheroids reduce disease severity, prevent relapse, and s
May 11, 2026
Press
FibroBiologics announced a strategic expansion of its fibroblast-based platform to target Hantavirus pulmonary syndrome
Impact 4/10
May 5, 2026
SEC
FibroBiologics filed a DEFA14A (definitive additional proxy soliciting materials) on May 5, 2026, but the actual documen
DEFA14A — Impact 3/10
May 4, 2026
Press
FibroBiologics announced preclinical results suggesting that its human dermal fibroblast spheroid treatment may reduce i
Impact 3/10
May 4, 2026
Insider
GARCIA RUBEN A was granted 61,607 shares
General Counsel
May 4, 2026
Insider
Davis Jason was granted 61,607 shares
Chief Financial Officer
May 4, 2026
Insider
O'HEERON PETE was granted 92,410 shares
CHIEF EXECUTIVE OFFICER
Apr 30, 2026
SEC
FibroBiologics reported Q1 2026 EPS of -$0.60, a 55.7% beat vs consensus of -$1.35, but net loss was flat YoY at $5.0M.
PRESS-RELEASE — Impact 5/10
Price Targets
$13.50
+1350.1% upside
Strong Buy
Current $0.9310
Low $8.00
Median $13.50
High $19.00
2 analysts
$8.00
$19.00
Analyst Ratings
2Strong Buy
4Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 4, 2026 | Maxim Group | DOWNGRADE | Buy → Hold |
| Apr 16, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 26, 2026 | D. Boral Capital | DOWNGRADE | Buy → Hold |
| Mar 12, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Feb 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.93 ▼ -21.6% | $-0.93 — $-0.93 | 61% YoY | 1 |
| Next Q | $-0.94 ▼ -22.1% | $-0.94 — $-0.94 | 64% YoY | 1 |
| Current FY | $-4.01 ▼ -8.2% | $-4.01 — $-4.01 | 52% YoY | 1 |
| Next FY | $-4.49 ▼ -16.8% | $-4.49 — $-4.49 | -12% YoY | 1 |
Latest Reports
NEUTRAL
Press
4/10
FibroBiologics announced a strategic expansion of its fibroblast-based platform to target Hantavirus pulmonary syndrome
May 11, 2026
NEUTRAL
DEFA14A
3/10
FibroBiologics filed a DEFA14A (definitive additional proxy soliciting materials) on May 5, 2026, but the actual documen
May 5, 2026
NEUTRAL
PRESS-RELEASE
5/10
FibroBiologics reported Q1 2026 EPS of -$0.60, a 55.7% beat vs consensus of -$1.35, but net loss was flat YoY at $5.0M.
Apr 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $89.3K | — |
| BlackRock, Inc. | $32.5K | — |
| RENAISSANCE TECHNOLOGIES LLC | $21.1K | — |
| VANGUARD FIDUCIARY TRUST CO | $8.4K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 4, 2026 | GARCIA RUBEN | A | $0.00 |
| May 4, 2026 | Davis Jason | A | $0.00 |
| May 4, 2026 | O'HEERON PETE | A | $0.00 |
| May 4, 2026 | Khoja Hamid | A | $0.00 |
| Mar 4, 2026 | Khoja Hamid | BUY | $11.4K |
8 institutional holders with $152.1K total value (115,434 shares) as of 2026-Q1. Top holders: ROYAL, VANGUARD, BlackRock,.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 186 | $0.00 | 0.0% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 67,665 | $89.3K | 58.7% | — |
| 3 | BlackRock, Inc. | 24,647 | $32.5K | 21.4% | — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 15,997 | $21.1K | 13.9% | — |
| 5 | VANGUARD FIDUCIARY TRUST CO | 6,380 | $8.4K | 5.5% | — |
| 6 | Vanguard Global Advisers, LLC | 536 | $708.00 | 0.5% | — |
| 7 | Allworth Financial LP | 13 | $18.00 | 0.0% | — |
| 8 | WELLS FARGO & COMPANY/MN | 10 | $13.00 | 0.0% | — |
4 unique insiders with 10 transactions. Net insider value: $73.0K ($73.0K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 4, 2026 | GARCIA RUBEN A | General Counsel | AWARD | 61,607 | — | — |
| May 4, 2026 | Davis Jason | Chief Financial Officer | AWARD | 61,607 | — | — |
| May 4, 2026 | O'HEERON PETE | CHIEF EXECUTIVE OFFICER | AWARD | 92,410 | — | — |
| May 4, 2026 | Khoja Hamid | Chief Scientific Officer | AWARD | 61,607 | — | — |
| Mar 4, 2026 | Khoja Hamid | Chief Scientific Officer | BUY | 30,000 | $0.3800 | $11.4K |
| Mar 4, 2026 | O'HEERON PETE | CHIEF EXECUTIVE OFFICER | BUY | 15,872 | $0.3784 | $6.0K |
| Mar 3, 2026 | O'HEERON PETE | CHIEF EXECUTIVE OFFICER | BUY | 18,200 | $0.4051 | $7.4K |
| Mar 2, 2026 | Davis Jason | Chief Financial Officer | BUY | 70,000 | $0.4139 | $29.0K |
| Mar 2, 2026 | O'HEERON PETE | CHIEF EXECUTIVE OFFICER | BUY | 17,428 | $0.3530 | $6.2K |
| Feb 27, 2026 | GARCIA RUBEN A | General Counsel | BUY | 40,000 | $0.3264 | $13.1K |
8 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 6 neutral. Avg impact: 4.8/10.
NEUTRAL
DEFA14A
3/10
FibroBiologics filed a DEFA14A (definitive additional proxy soliciting materials) on May 5, 2026, bu
May 5, 2026
NEUTRAL
PRESS-RELEASE
5/10
FibroBiologics reported Q1 2026 EPS of -$0.60, a 55.7% beat vs consensus of -$1.35, but net loss was
Apr 30, 2026
NEUTRAL
8-K
5/10
FibroBiologics announced it has regained compliance with all Nasdaq listing requirements, including
Apr 20, 2026
NEUTRAL
8-K
5/10
FibroBiologics, Inc. executed a 1-for-20 reverse stock split effective March 30, 2026, reducing its
Apr 3, 2026
BEARISH
424B4
6/10
FibroBiologics has priced a $3M equity offering of common stock, pre-funded warrants, and accompanyi
Apr 1, 2026
NEUTRAL
EFFECT
5/10
FibroBiologics' S-1 registration has become effective, allowing the company to proceed with its plan
Apr 1, 2026
BULLISH
CLUSTER
6/10
Multiple C-suite executives at FibroBiologics, including the CEO, CFO, and Chief Scientific Officer,
Mar 5, 2026
NEUTRAL
CLUSTER
3/10
Two corporate insiders at FibroBiologics, Inc. (FBLG) — the CFO and General Counsel — purchased shar
Mar 3, 2026
NEUTRAL
4/10
FibroBiologics announced a strategic expansion of its fibroblast-based platform to target Hantavirus
May 11, 2026
NEUTRAL
3/10
FibroBiologics announced preclinical results suggesting that its human dermal fibroblast spheroid tr
May 4, 2026
NEUTRAL
4/10
FibroBiologics announced the release of the first cGMP batch of its CYWC628 drug product for a Phase
May 4, 2026
BEARISH
6/10
FibroBiologics (FBLG) announced the pricing of a $3 million public offering of 2.27 million shares a
Apr 1, 2026
NEUTRAL
4/10
FibroBiologics announced the issuance of a new U.S. patent (No. 12,544,407 B2) for its fibroblast ce
Mar 2, 2026
Current analyst consensus: Buy (75% buy). Based on 8 analysts: 2 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$13.50 mean target
+1350.1% upside
Strong Buy (3.00)
$8.00 Low
$19.00 High
| Metric | Value |
|---|---|
| Current Price | $0.9310 |
| Target Low | $8.00 |
| Target Mean | $13.50 |
| Target Median | $13.50 |
| Target High | $19.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.93 | $-0.93 | $-0.93 | 61.3% | -21.6% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.94 | $-0.94 | $-0.94 | 63.8% | -22.1% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-4.01 | $-4.01 | $-4.01 | 52.3% | -8.2% | 2↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-4.49 | $-4.49 | $-4.49 | -12.0% | -16.8% | 2↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.930 | |
| 7d ago | $-0.765 | -0.165 |
| 30d ago | $-0.765 | -0.165 |
| 60d ago | $-1.000 | +0.070 |
| 90d ago | $-2.200 | +1.270 |
3 analyst firms have rated this stock: 0 upgrades, 2 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 4, 2026 | Maxim Group | DOWNGRADE | Buy | Hold |
| Apr 16, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 26, 2026 | D. Boral Capital | DOWNGRADE | Buy | Hold |
| Mar 12, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Feb 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 25, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 6, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| May 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Apr 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Mar 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 22, 2026
routine
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
In animal studies, human dermal fibroblast spheroids reduce disease severity, prevent relapse, and suppress key inflammatory pathways associated with
May 11, 2026
fda
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
Will Apply Existing Preclinical Findings in Reducing Severe Immune-Mediated Lung Failure to Potential Emerging Global Crisis <pre>Will Apply Existing
May 4, 2026
fda
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
<p align="justify">HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology
May 4, 2026
fda
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
<p align="justify">HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology
Apr 30, 2026
earnings
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
On track for first patient dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers in Q2 of 2026 <pre>On track for first patient
Apr 30, 2026
routine
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
<p align="justify">HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnolog
Apr 20, 2026
other
FibroBiologics Compliant with All Nasdaq Listing Requirements
<p align="justify">HOUSTON, April 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnolog
Apr 10, 2026
other
FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity
Preclinical models demonstrate potential to restore thymic function lost with aging reducing susceptibility to cancer, autoimmune diseases, infections
Apr 2, 2026
offering
FibroBiologics Announces Closing of $3 Million Public Offering
<p align="justify">HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) (“FibroBiologics” or the “Company”), a clinical-s
Apr 1, 2026
short_volume
Short Volume: FBLG — 55.7% short (1.4M / 2.6M)
Short: 1,427,398 | Exempt: 187,619 | TRF Vol: 2,564,949 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
short_interest
FTD: FBLG — 1,226,462 shares ($1.6M) failed to deliver
Settlement: 20260401, Price: $1.32, FTD Value: $1,618,929.84, FIBROBIOLOGICS INC COM NEW
Apr 1, 2026
offering
FibroBiologics Announces Pricing of $3 Million Public Offering
<p align="justify">HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) (“FibroBiologics” or the “Company”), a clinical-s
Mar 31, 2026
other
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial
<p align="justify">HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnolo
Mar 31, 2026
short_volume
Short Volume: FBLG — 77.6% short (0.5M / 0.6M)
Short: 481,393 | Exempt: 23,985 | TRF Vol: 620,465 | Short Ratio: 77.6% | Off-exchange volume (dark pool + OTC)
Mar 27, 2026
short_volume
Short Volume: FBLG — 66.1% short (0.7M / 1.0M)
Short: 673,778 | Exempt: 24,423 | TRF Vol: 1,019,797 | Short Ratio: 66.1% | Off-exchange volume (dark pool + OTC)